University of Glasgow
Development of a protocol to study novel radiotherapy-immunotherapy combinations in pre-clinical models of locally advanced rectal cancer
Abstract
dc:description.abstractHeterogeneous responses to neo-adjuvant chemoradiotherapy are observed in Locally Advanced Rectal Cancer (LARC). Understanding the molecular and immunological factors underpinning response to radiotherapy-based treatment strategies may promote the development of novel treatment strategies to overcome resistance mechanisms and improve response rates. Murine models of LARC and experimental platforms to deliver precise radiotherapy to small animals, will enable the pre-clinical testing and development of radiotherapy and immunotherapy combinations to guide future clinical trials. Despite numerous technological advances in pre-clinical modelling of CRC, models which recapitulate the anatomy and mutational composition of LARC have been lacking. In Chapter 3, I describe the development of a novel orthotopic organoid transplant model which recapitulates histological features of aggressive disease, expresses common driver mutations, and maintains immunocompetence. Furthermore, the described model demonstrates reproducibility, high engraftment and is amenable to high experimental throughput. In Chapter 4, I then utilise the developed orthotopic model of LARC to demonstrate that precise delivery of clinically relevant fractionated radiotherapy is possible in the pre-clinical setting. I then performed irradiation studies to characterise the effects of single fraction and fractionated radiotherapy to the model developed in thesis. In Chapter 4, I characterise the radio-resistance of the orthotopic model of LARC which has been developed, and identify numerous potential resistance mechanisms. In Chapter 5, I then show the feasibility of administering fractionated radiotherapy and immunotherapy agents to an orthotopic model of LARC. Improved survival was demonstrated following treatment with fractionated radiotherapy and PD-1 inhibition. Overall, this thesis describes significant advances in the pre-clinical modelling of LARC and experimental capabilities for developing novel radiotherapy and immunotherapy combinations, which hold potential to inform the treatment scheduling of fractionated radiotherapy and PD-1 inhibition.
Degree
thesis:*- Level dc:type.qualificationlevel
- PhD
- Grantor dc:publisher.institution
- University of Glasgow
- Year dc:date.issued
- 2024
Author and committee
dc:creator, dc:contributor.*- Author dc:creator
-
- Gillespie, Michael A.
Subjects
dc:subject × 2Rights
- Language dc:language
- en
Identifiers
dc:identifier.*- DOI dc:identifier.doi
- https://doi.org/10.5525/gla.thesis.84221